|
Description Nicergoline is a kind of ergot alkaloid, which can dilatate the blood vessel of brain and improve the blood supply of brain. It can block α-receptor and accelerate metabolism as well as reduce the resistance of the blood vessel of brain and increase the blood flow of brain and the usage of glucose to improve mental retardation. Nicergoline can also accelerate the metabolism of dopamine, enhance the nerve conduction, improve the mental and emotional abnormality, accelerate the synthesis of the protein in brain, effectively improve memory, recover the normal function of nerve cells, entirely improve the clinic symptom of chronic brain dysfunction syndrome. Nicergoline is first researched and produced by Pfizer Co., Ltd., which is widely used for many indications. It spreads to the globe after launching to the market. Market size of nicergoline and its share in anti-Alzheimer's disease drug market is small as a drug used for 30 years. There are many substitutes and its product lifecycle is in recession. According to CRI's market research, the market size of nicergoline in sample hospitals was about CNY 89 million in 2010 and CNY 76 million in 2014. In future years, China's nicergoline market will shrank because of the competition of other types of anti-AD drugs like biopharmaceuticals. However, the low-end market demand for nicergoline still exists, the nicergoline drug market won't disappear in a short time. Through this report, readers can acquire the following information:
-Sales price of nicergoline in hospital market in China
-Market Share of Major Nicergoline Manufacturers in China
-Patent Status of Nicergoline in China
-Market share of Nicergoline by dosage form in hospital market in China
-Prospect of China Nicergoline Market The Following Enterprises and People Are Recommended to Purchase This Report:
- manufacturers of drug for cardiovascular disease and Alzheimer’s disease
-Investors Focusing on China Drug Market
-CRI also provides other drug market report and custom research.
|
Login
Location : 
